Ocrevus Slows Disability Progression in Advanced PPMS, Trial Finds

Why It Matters

The findings broaden Ocrevus’s therapeutic reach to older and more disabled PPMS patients, addressing a critical unmet need and reinforcing its market position as the sole disease‑modifying option for this form of MS.

Key Takeaways

• Ocrevus cut confirmed disability progression risk by 30% in PPMS.
• Hand and arm function decline reduced 41% versus placebo.
• Efficacy held across ages up to 65 and high baseline disability.
• Safety profile unchanged; infusion reactions most common adverse event.
• Trial enrolled over 1,000 patients, median follow‑up nearly three years.

Pulse Analysis

Primary progressive multiple sclerosis (PPMS) has long been the most challenging MS subtype to treat, with few disease‑modifying therapies approved and limited options for patients with advanced disability. Ocrevus, the only FDA‑approved agent for PPMS, previously demonstrated modest benefits in younger, less disabled cohorts. The new ORATORIO‑HAND data, presented at the 2026 American Academy of Neurology meeting, expands that evidence base by targeting a broader, more representative patient population, including individuals up to 65 years old and those with substantial functional impairment.

The trial’s robust design—over 1,000 participants, double‑blind randomization, and a median exposure of nearly three years—provides high‑quality evidence that Ocrevus can meaningfully delay disability progression. A 30% relative risk reduction in confirmed progression, coupled with a 41% drop in hand‑arm functional decline, signals a tangible improvement in daily living activities for patients who often face rapid loss of independence. Importantly, the therapeutic effect persisted regardless of baseline MRI activity, gender, or disability severity, suggesting a disease‑modifying mechanism that operates across the disease spectrum.

For clinicians and payers, these results may shift prescribing patterns, encouraging earlier adoption of Ocrevus in patients previously deemed too advanced for treatment. The consistent safety profile—infusion reactions being the primary concern—reinforces confidence in long‑term use. Market analysts will likely view the data as a catalyst for sustained demand, while researchers may explore combination strategies to further enhance outcomes. Ultimately, the study offers renewed hope for a patient group that has historically faced limited therapeutic hope, underscoring the importance of inclusive trial designs in chronic neuro‑degenerative diseases.